9 results about "Non targeted metabolomics" patented technology

The application belongs to the technical field of biological medicine, and discloses application of NP in preparation of a preparation for regulating metabolism of the intestines of senile type 2 diabetes. The NP is formed by hydrogen bond combination of a peptide from soft-shelled turtle eggs with naringenin in a mass ratio of 100:1, and the mass of the peptide is less than 3 kDa; the preparation is used for regulating phenotype-related metabolic modules and intestinal micro-ecological-related metabolic modules, remodeling the intestinal metabolic regulation network taking differential metabolites as a bridge, and thus systemically improving metabolic disorders related to senile type 2 diabetes. It is found that NP intervention can obviously correct abnormal total metabolic profiles of feces of senile type 2 diabetes mice, and make the disease type metabolic profile shift to a new steady state of intervention type. Non-targeted metabolomics analysis by LC-MS / MS shows that the overall metabolic profile of the high-dose NP group is closer to that of the classic hypoglycemic drug metformin group, indicating that NP has a significant metabolic remodeling capacity.

The application discloses a kind of based on metabolic pathway analysis's Iresine heratensis fermentation quality regulation method, it is related to food biotechnology field, including, the sample of different varieties Iresine heratensis is obtained, carries out non-targeted metabolomics analysis, obtains metabolite spectrum data;The metabolite spectrum data carries out difference analysis, constructs key difference metabolite dataset;Metabolic pathway enrichment analysis is carried out to the key difference metabolite dataset, determines core metabolic pathway;Regulate the process parameter in Iresine heratensis fermentation process, obtain the fermentation product after regulation;The quality of the fermentation product after regulation is verified, feedback optimization the process parameter, form closed loop quality regulation method;The application is determined core metabolic pathway by constructing key difference metabolite dataset and enrichment analysis, realizes from traditional experience type fermentation process optimization to the change of accurate regulation based on metabolic mechanism, solves the problem that fermentation quality in prior art is greatly blind, target is not clear.

This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.

The application discloses a biomarker of calcific aortic valve disease and application thereof, and belongs to the technical field of biological medicine. In the application, through non-targeted metabolomics discovery, serotonin deficiency can be a novel independent biomarker of calcific aortic valve stenosis. Specifically, receiver operating characteristic curve analysis shows that serotonin has good diagnostic efficiency for CAVD, and the optimal cutoff value is 148.2 ng / mL. Therefore, it is found in the application that the level of serotonin in CAVD patients is reduced, and the reduction is irrelevant to the severity of the disease, indicating that the serotonin has the potential to serve as a diagnostic biomarker.

This invention belongs to the field of biomedical technology and discloses the application of the small molecule tripeptide Ser-Ser-Cys (SSC) in inhibiting the phenotypic transformation of vascular smooth muscle cells (VSMCs). SSC is an endogenous differentially expressed tripeptide screened and identified from the serum of hypertensive non-atherosclerotic patients using non-targeted metabolomics technology. In vitro experiments show that SSC can effectively inhibit angiotensin II (Ang II)-induced abnormal proliferation, migration, and phenotypic transformation from contractile to synthetic VSMCs. Its mechanism of action is related to the regulation of the Keap1 / Nrf2 signaling pathway, improvement of cellular oxidative stress, and mitochondrial function. This invention provides a new approach for using SSC in the preparation of drugs or functional foods for the prevention and treatment of hypertension-related vascular remodeling.

The application discloses a biomarker combination, a kit and a system for evaluating the curative effect of lung adenocarcinoma targeted therapy. The biomarker combination is composed of sphingosine base metabolites, 3-methyl-2-piperidone and 4-hydroxydodecanedioyl carnitine. Through non-targeted metabolomics combined with LASSO regression algorithm (lasso regression), the application accurately locks three key markers highly related to EGFR gene mutation lung adenocarcinoma targeted therapy from numerous differential metabolites, and constructs an auxiliary evaluation system. Verification shows that the combination and system have very high sensitivity and specificity in distinguishing disease progression PD and partial remission PR, and the AUC value is greater than 0.95. The application has the advantages of minimally invasive, accurate and objective based on ex vivo serum detection, and provides an important kit and system for dynamic monitoring of lung adenocarcinoma targeted therapy.

This invention discloses a method for screening optimal metabolite feature combinations for non-targeted metabolomics data. By injecting the topological robustness score (TRS) and prior weights obtained in step S1 into the dynamic fitness function calculation in the genetic algorithm screening process in step S2, it is ensured that the selected optimal metabolite feature combinations not only have high classification efficiency, but also are all located in the core functional modules of the biological network, reducing the interference of spurious markers. Therefore, this invention can significantly improve the biological interpretability of metabolite biomarker combination screening while meeting the constraint of the ideal number of selected metabolite features.

This invention provides the application of metabolite biomarkers in the preparation of products for diagnosing hyperuricemia and a device for diagnosing hyperuricemia, belonging to the field of biomedical technology. This invention utilizes non-targeted metabolomics technology to systematically analyze the fecal metabolic profiles of a population cohort, and comprehensively employs differential analysis, partial least squares discriminant analysis (PLS-DA), and machine learning algorithms to screen and identify core fecal metabolic biomarkers (caustic acid, cowagarcinone E, and tuliposide B) from a massive amount of metabolites that can reliably predict the tendency to develop hyperuricemia. Finally, a predictive device based on this biomarker combination was established. This device has high predictive accuracy and provides a novel, non-invasive tool with high clinical translational potential for early screening and risk stratification of hyperuricemia.

This invention discloses the application of N-palmitoyl sphingosine in the preparation of anti-inflammatory drugs. Through non-targeted metabolomics analysis of mouse feces, the differences in gut microbiota metabolites caused by a high-salt diet were compared. The results showed that a high-salt diet altered the composition of gut microbiota metabolites, and that these metabolites play a crucial role in the progression of inflammation induced by a high-salt diet. This invention also reveals that supplementation with N-palmitoyl sphingosine can alleviate inflammation induced by a high-salt diet, providing a novel candidate drug for intervening in high-salt diet-related inflammation.